Chemo-prevention in superficial bladder cancer using mitomycin C: A survey of the practice patterns of British urologists

BJU International

Volumn 97, Issue 4, 2006, Pages 716-719

  Clarke, Nicholas S ^a,c   Basu, Saurajyoti ^a   Prescott, Steven ^b   Puri, Rajiv ^a  

^a BRADFORD ROYAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

BCG; Bladder cancer; Mitomycin C; Practice; Survey

Indexed keywords

MITOMYCIN C;

ADULT; BLADDER CANCER; CANCER RECURRENCE; CARCINOMA IN SITU; CHEMICAL CYSTITIS; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CONSULTATION; CONTACT DERMATITIS; DRUG EFFICACY; DRUG INSTILLATION; DRUG TOLERABILITY; DRUG USE; HUMAN; MAINTENANCE THERAPY; MEDICAL PRACTICE; NEPHRECTOMY; NORMAL HUMAN; PERCEPTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SINGLE DRUG DOSE; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; UNITED KINGDOM; UROLOGY;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; HUMANS; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; QUESTIONNAIRES; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 33644921781     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.05970.x     Document Type: Review

References (14)

1. Hall RR Superficial bladder cancer BMJ 1994 308 910 3
2. Lutzeyer W Rubben H Dahm H Prognostic parameters in superficial bladder cancer: an analysis of 315 cases J Urol 1982 127 250 2
3. Tolley DA Parmar MK Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up J Urol 1996 155 1233 8
4. Oosterlinck W Kurth KH Schroder F Bultinck J Hammond B Sylvester R A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder J Urol 1993 149 749 52
5. Smith JA Labasky RF Cockett AT Fracchia JA Montie JE Rowland RG Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association J Urol 1999 162 1697 701
6. Bohle A Jocham D Bock PR Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 2003 169 90 5
7. Oosterlinck W Lobel B Jakse G Malmstrom PU Stockle M Sternberg C European Associations of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer Eur Urol 2002 41 105 12
8. Oosterlinck W Guidelines on diagnosis and treatment of superficial bladder cancer Minerva Urol Nefrol 2004 56 65 72
9. Kaasinen E Rintala E Hellstrom P et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma Eur Urol 2002 42 167 74
10. Shelley MD Wilt TJ Court J Coles B Kynaston H Mason MD Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials BJU Int 2004 93 485 90
11. Patard JJ Rodriguez A Lobel B The current status of intravesical therapy for superficial bladder cancer Curr Opin Urol 2003 13 357 62
12. Sakamoto N Naito S Kotoh S et al. Recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract Eur Urol 1991 20 136 9
13. Krogh J Kvist E Rye B Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences Br J Urol 1991 67 32 6
14. Sakamoto N Naito S Kumazawa J et al. Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study Int J Urol 2001 8 212 6